Comparing Ocular AEs in Next-Gen Treatments

What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.